TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7341065
Drug: Tobramycin Ointment
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin Ointment
Study: 28642210
Drug: Aspirin 100mg
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 100mg for 1 year
Study: 28642210
Drug: Aspirin 100mg
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 100mg + PPI for 1 year
Study: 25990828
Drug: High molecular
Normalized name: dextran, high molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: High molecular weight sodium hyaluronate (SH) at a dosage of 9 mg three times a day for 30 days
Study: 23683447
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 40mL of 0.25% lidocaine with 0.05mg fentanyl and 0.5mg vecuronium (n=30)
Study: 21159683
Drug: 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg misoprostol administered 3 hours prior to IUD insertion
Study: 21159683
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered 3 hours prior to IUD insertion
Study: 19002702
Drug: Bupropion (BUP)
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion (BUP) 300 mg for 7 days after 150 mg for 3 days
Study: 17701883
Drug: Propylthiouracil (6-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propylthiouracil (6-8 mg/kg/day)
Study: 15651715
Drug: Propofol (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (8 mg/kg for the first 30 min, followed by 6 mg/kg for maintenance in a 50% O2/N2O mixture)
Study: 10063490
Drug: mecamylamine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: mecamylamine (2.5 mg tablet)
Study: 2180995
Drug: 2% and
Normalized name: clindamycin phosphate 12 mg in 1 g / tretinoin 0.25 mg in 1 g TOPICAL GEL [Clindamycin Phosphate 1.2% and Tretinoin 0.025%]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% and 3% topical minoxidil
Study: 759879
Drug: Penicillamine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillamine (600 to 900 mg)
Study: 30891960
Drug: community treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: community treatment as usual (TAU)
Study: 21219984
Drug: DTaP‐IPV//PRP‐T combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP‐IPV//PRP‐T combined vaccine (Pentaxim(®))
Study: 21219984
Drug: Individual vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual vaccines (DTaP, PRP‐T, IPV)
Study: 19320245
Drug: Zidovudine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (300 mg twice daily) from 28 weeks of gestational age to delivery
Study: 16626956
Drug: Tiotropium (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (18 microg dry powder capsules delivered via HandiHaler once daily)
Study: 16626956
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Formoterol and Tiotropium
Study: 16626956
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (Formoterol, Tiotropium, Combination)
Study: 14517774
Drug: Daily rhGH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily rhGH therapy (D)
Study: 14517774
Drug: Alternate-day rhGH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate-day rhGH therapy (A)
Study: 10882958
Drug: Omeprazole and
Normalized name: Omeprazole and Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole and antibiotics for H pylori eradication
Study: 8882989
Drug: Cisplatin (CDDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CDDP) 60 mg/m2, Carboplatin (CBDCA) 200 mg/m2, Etoposide (VP-16) 100 mg/m2 (Step 2)
Study: 8882989
Drug: Cisplatin (CDDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CDDP) 60 mg/m2, Carboplatin (CBDCA) 250 mg/m2, Etoposide (VP-16) 100 mg/m2 (Step 3)
Study: 1373366
Drug: TENS (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: TENS (15 daily 60 min treatments over 3 weeks)
Study: 30835327
Drug: CoQ10 300
Normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CoQ10 300 mg daily
Study: 15987228
Drug: Adjustable maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjustable maintenance dosing (one inhalation twice daily, stepping up to four inhalations twice daily for 1 week if asthma worsened)
Study: 15987228
Drug: Fixed dosing
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dosing (two inhalations twice daily)
Study: 12826844
Drug: Dexmedetomidine (0.075,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.075, 0.15, 0.3, and 0.6 ng/mL)
Study: 12826844
Drug: Dexmedetomidine (0.15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.15, 0.3, and 0.6 ng/mL)
Study: 10469307
Drug: Low-intensity laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity laser therapy (wavelength 690 nm, intensity: 80 mW per cm2, dose: 48 J per cm2)
Study: 8708523
Drug: Oral lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral lidocaine (50 mg)
Study: 10521742
Drug: Oral nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nifedipine (10 mg)
Study: 1789830
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration therapy (by mouth or nasogastric tube)
Study: 6308488
Drug: Hydrochlorothiazide, 50
Normalized name: HydroCHLOROthiazide, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide, 50 mg p.d.
Study: 24240647
Drug: Individualized, moderate-intensity,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized, moderate-intensity, 12-week home-based exercise program with weekly telephone support from a certified exercise physiologist
Study: 7772916
Drug: Left intraatrial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left intraatrial infusion of prostaglandin E1 (PGE1) at 0.003 microgram/kg/min
Study: 7772916
Drug: Right intraatrial
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Right intraatrial infusion of prostaglandin E1 (PGE1) at 0.03 microgram/kg/min
Study: 7017680
Drug: NSAI drugs
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NSAI drugs (replacing steroids)
Study: 6420959
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (steroids)
Study: 25869024
Drug: Superficial cervical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superficial cervical plexus block (SCPB) with 0.25% bupivacaine, 10 mL
Study: 23996765
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion at 0.5 µg·kg(‐1)·h(‐1)
Study: 21337541
Drug: N-acetyl-L-cysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetyl-L-cysteine (NAC) 100 mg/kg/day
Study: 21337541
Drug: N-acetyl-L-cysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetyl-L-cysteine (NAC) moderate levels (0.4-3.2 mM)
Study: 21337541
Drug: N-acetyl-L-cysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetyl-L-cysteine (NAC) high concentrations (12.5-50 mM)
Study: 15129994
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of SLS-irritated skin with urea and placebo
Study: 1433586
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (Cohen technique in 52% and Politano‐Leadbetter technique in 28%)
Study: 6149128
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg carvedilol (invasive study)
Study: 6149128
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg carvedilol (non-invasive study)
Study: 6149128
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg carvedilol (non-invasive study)
Study: 6149128
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg carvedilol (all groups)
Study: 27366396
Drug: Esmolol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (2 mg kg(‐1) infused over 10 min)
Study: 27366396
Drug: Control (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (50 mL saline infused over 10 min)
Study: 18051009
Drug: 10% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% carbamide peroxide (CP) bleaching agent - Opalescence
Study: 18051009
Drug: 10% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% carbamide peroxide (CP) bleaching agent - Opalescence PF (3% potassium nitrate and 0.11% fluoride)
Study: 18051009
Drug: 10% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% carbamide peroxide (CP) bleaching agent - Nite White Excel 3 (ACP)
Study: 18051009
Drug: 10% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% carbamide peroxide (CP) bleaching agent - Opalescence + F (acidulated phosphate fluoride 1.23%)
Study: 18051009
Drug: 10% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% carbamide peroxide (CP) bleaching agent - Opalescence PF + F
Study: 18051009
Drug: 10% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% carbamide peroxide (CP) bleaching agent - Nite White Excel 3 + F
Study: 12404706
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba (120 mg)
Study: 10323378
Drug: Low insulin-ante-hypo
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low insulin-ante-hypo (1.5 mU/min x kg)
Study: 10323378
Drug: High insulin-ante-hypo
Normalized name: High molecular weight insulin human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High insulin-ante-hypo (15.0 mU/min x kg)
Study: 8540928
Drug: Sandoglobulin (SG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandoglobulin (SG) (0.5 g/kg/day)
Study: 8540928
Drug: Pentaglobin (PG)
Normalized name: PG
DrugBank: Pentaglobin (DB15865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentaglobin (PG) (5 mL/kg/day)
Study: 8540928
Drug: Both IVIG
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both IVIG preparations (SG and PG)
Study: 31946903
Drug: Remifentanil effect‐compartment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil effect‐compartment target controlled infusion (Ceremi) of 1 ng/ml
Study: 31946903
Drug: Remifentanil effect‐compartment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil effect‐compartment target controlled infusion (Ceremi) of 3 ng/ml
Study: 31946903
Drug: Remifentanil effect‐compartment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil effect‐compartment target controlled infusion (Ceremi) of 5 ng/ml
Study: 31946903
Drug: Remifentanil effect‐compartment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil effect‐compartment target controlled infusion (Ceremi)
Study: 20965755
Drug: GTN (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTN (0.9 mg sublingual)
Study: 19923521
Drug: 1.5 L
Normalized name: NUTREN 1.5 LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 L crystalloid (Hartman's solution)
Study: 19923521
Drug: 0.5 L
Normalized name: AIR 20.5 L in 100 L RESPIRATORY (INHALATION) GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 L of 6% w/v hydroxyethyl starch (HES) solution (HES 0.5)
Study: 19923521
Drug: 1 L
Normalized name: BLUE 1 LAKE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 L of 6% w/v HES solution (HES 1.0)
Study: 17199235
Drug: donepezil 5
Normalized name: donepezil 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: donepezil 5 mg/day
Study: 15129975
Drug: Mini-matrix formulation
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini-matrix formulation F-1 (30% ibuprofen, 35% ethyl cellulose, 35% hydroxypropyl methylcellulose)
Study: 15129975
Drug: Mini-matrix formulation
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini-matrix formulation F-2 (60% ibuprofen, 20% ethyl cellulose, 20% xanthan gum)
Study: 11313163
Drug: Sumatriptan 100
Normalized name: sumatriptan 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan 100 mg/day
Study: 3282846
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg once daily for four weeks
Study: 9055715
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg once daily for eight weeks
Study: 3282846
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg twice daily for four weeks
Study: 3282846
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg twice daily for eight weeks
Study: 31192555
Drug: Oat porridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat porridge (70 grams daily for 4 weeks)
Study: 25167799
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy (PAC) - proton pump inhibitor with amoxicillin and clarithromycin twice a day for 7 days
Study: 25167799
Drug: Pronase combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pronase combined with standard triple therapy (PACE) - pronase (20,000 tyrosine units) with proton pump inhibitor, amoxicillin, and clarithromycin twice a day for 7 days
Study: 21715572
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg/day, titrated to 100 mg/day after 6 weeks
Study: 10905362
Drug: LAC 400
Normalized name: etodolac 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAC 400 regimen (400 mg clarithromycin)
Study: 10905362
Drug: LAC 800
Normalized name: Lac
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAC 800 regimen (800 mg clarithromycin)
Study: 8833461
Drug: Negative control
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative control (compound with low irritant potential)
Study: 1418278
Drug: Lytic solution
Normalized name: Fytic acid
DrugBank: Phytic acid (DB14981)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lytic solution
Study: 2568785
Drug: Iohexol 240
Normalized name: iohexol 240 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iohexol 240 mg I/ml
Study: 3882611
Drug: Meglumine‐Ca metrizoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meglumine‐Ca metrizoate 200 mg I/ml
Study: 31929374
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg IV ibuprofen administered every 6 hours for a total of 8 doses within 48 hours
Study: 31929374
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered every 6 hours for a total of 8 doses within 48 hours
Study: 26250833
Drug: Ivacaftor 150
Normalized name: ivacaftor 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivacaftor 150 mg every 12 hours for 48 weeks
Study: 24999369
Drug: Avatar therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avatar therapy (6 sessions of 30 minutes each)
Study: 20494464
Drug: Oral professional
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral professional care with mucosal care
Study: 20494464
Drug: Oral professional
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral professional care without mucosal care
Study: 18831889
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg 0.5% bupivacaine plus 25 microg fentanyl (group BF)
Study: 18831889
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg 0.5% bupivacaine alone (group B)
Study: 9223885
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose midazolam (MZ) administered i.v. at doses of 0, 0.03, 0.06 mg.kg‐1
Study: 2957057
Drug: Late patency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late patency of the infarct related vessel postthrombolytic therapy without angioplasty
Study: 26643541
Drug: NSI-189 40
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NSI-189 40 mg q.d. (n=6)
Study: 26643541
Drug: NSI-189 40
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NSI-189 40 mg b.i.d. (n=6)
Study: 26643541
Drug: NSI-189 40
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NSI-189 40 mg t.i.d. (n=6)
Study: 23693155
Drug: Pharmacist-led smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led smoking cessation intervention with at least three support sessions (during hospital stay, post-discharge, and within one month post-discharge) and free smoking cessation medications during hospital stay and for at least one week after discharge.
Study: 9375336
Drug: Beta-blockade (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockade (100 mg atenolol) before training
Study: 9375336
Drug: Beta-blockade (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockade (100 mg atenolol) after training
Study: 8298585
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 3 g fosfomycin trometamol
Study: 8298585
Drug: Seven days
Normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seven days of nitrofurantoin 50 mg four times daily
Study: 3236329
Drug: Torasemide 2.5
Normalized name: Torasemide 2.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide 2.5 mg once daily
Study: 24320900
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing (SRP) combined with metronidazole (MTZ) + amoxicillin (AMX) for 14 days
Study: 3140592
Drug: Dihydroergocristine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergocristine (10 mg capsules, twice a day for 5 days, then 3 times a day for 5 days if treatment failed)
Study: 3140592
Drug: Bromocriptine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (2.5 mg capsules, twice a day for 5 days, then 3 times a day for 5 days if treatment failed)
Study: 30075534
Drug: Tofacitinib 5
Normalized name: tofacitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 5 mg and 10 mg BID
Study: 18638266
Drug: Topical Negative
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Negative Pressure (TNP) therapy
Study: 28583732
Drug: Control (regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (regular topical dressings)
Study: 17976264
Drug: Dextrose solution
Normalized name: Dextrose solution
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose solution
Study: 17175820
Drug: Tramadol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (100 mg every 8 hours)
Study: 17175820
Drug: Combined analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined analgesic (50 mg tramadol every 8 hours and 200 mg ibuprofen every 8 hours)
Study: 15015908
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy treatment (n=6, n=5)
Study: 10971455
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of melatonin orally during oestradiol replacement
Study: 8839900
Drug: Fadrozole, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fadrozole, 1 mg twice daily
Study: 7917929
Drug: Tamoxifen, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen, 20 mg daily
Study: 1531483
Drug: Fadrozole 4
Normalized name: Fadrozole
DrugBank: Fadrozole (DB16832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fadrozole 4 mg daily for 14 days
Study: 6829674
Drug: 50 burns
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 burns administered over one half the trabecular meshwork (Group 1)
Study: 6829674
Drug: 100 burns
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 burns administered over the entire trabecular meshwork (Group 2)
Study: 28917689
Drug: Early statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early statin group (pitavastatin 4 mg/day from baseline)
Study: 28917689
Drug: Late statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late statin group (pitavastatin 4 mg/day from 3 weeks after baseline)
Study: 17588581
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of Candesartan (32 mg)
Study: 17588581
Drug: Conventional doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional doses of Candesartan (16 mg)
Study: 25418492
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment other than ARBs or angiotensin-converting enzyme inhibitors (Control group)
Study: 19043945
Drug: Polymyxin B
Normalized name: Polymyxin B
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polymyxin B sulfate/trimethoprim, 1 drop four times daily for 7 days
Study: 19043945
Drug: 0.5% Moxifloxacin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% Moxifloxacin, 1 drop three times daily for 7 days
Study: 15021280
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg intravenous bolus of dexamethasone
Study: 20502415
Drug: High-dose CCB
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose CCB (group C)
Study: 20502415
Drug: High-dose ARB
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ARB (group D)
Study: 20502415
Drug: Low-dose combination
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose combination therapy (CCB plus ARB, group E)
Study: 18426826
Drug: I131 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: I131 treatment
Study: 18426826
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no I131 treatment)